{"date":"2025-12-08","count":12,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7799-2025-12-08-1919-1kdmpxd","company_id":"7799","company":"禾榮科","market":"上市","industry":"生技醫療","date":"2025-12-08","time":"19:19:10","subject":"本公司研發之F18 FBPA注射液向台灣衛生福利部食品藥物管理署(TFDA)提出學術研究用人體臨床試驗IND申請許可之申復進度更新","clause":"第10款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：禾榮科（7799），2025-12-08 19:19，「本公司研發之F18 FBPA注射液向台灣衛生福利部食品藥物管理署(TFDA)提出學術研究用人體臨床試驗IND申請許可之申」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4724-2025-12-08-1818-11al93r","company_id":"4724","company":"宣捷幹細胞","market":"興櫃","industry":"生技醫療","date":"2025-12-08","time":"18:18:33","subject":"本公司「人類臍帶間質幹細胞外泌體 (Human UmbilicalMesenchymal Stem Cell Exosomes)」粉末原料經美國個人護理產品協會(PCPC)審查通過，獲國際INCI原料認證(INCI name)","clause":"第44款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：宣捷幹細胞（4724），2025-12-08 18:18，「本公司「人類臍帶間質幹細胞外泌體 (Human UmbilicalMesenchymal Stem Cell Exoso」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4128-2025-12-08-1742-142h7my","company_id":"4128","company":"中天","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"17:42:12","subject":"代重要子公司棉花田生機園地股份有限公司公告監察人辭任事宜","clause":"第6款","fact_date":"2025-11-24","cite_as":"公開資訊觀測站重大訊息：中天（4128），2025-12-08 17:42，「代重要子公司棉花田生機園地股份有限公司公告監察人辭任事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6730-2025-12-08-1635-1kekmir","company_id":"6730","company":"常廣","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"16:35:07","subject":"公告本公司辦理股票初次上櫃前現金增資收足股款暨現金增資基準日","clause":"第44款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：常廣（6730），2025-12-08 16:35，「公告本公司辦理股票初次上櫃前現金增資收足股款暨現金增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7814-2025-12-08-1613-fzpsgg","company_id":"7814","company":"海昌生技","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"16:13:05","subject":"因應本公司上櫃申請需要委託簽證會計師出具內部控制制度審查確信報告(審查期間113/10/01~114/09/30)","clause":"第25款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：海昌生技（7814），2025-12-08 16:13，「因應本公司上櫃申請需要委託簽證會計師出具內部控制制度審查確信報告(審查期間113/10/01~114/09/30)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8432-2025-12-08-1610-w05472","company_id":"8432","company":"東生華","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"16:10:37","subject":"本公司受邀參加德信綜合證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-11","cite_as":"公開資訊觀測站重大訊息：東生華（8432），2025-12-08 16:10，「本公司受邀參加德信綜合證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2025-12-08-1610-107simy","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-08","time":"16:10:11","subject":"更正本公司114年第一次股東臨時會議事手冊及議案參考資料","clause":"第44款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2025-12-08 16:10，「更正本公司114年第一次股東臨時會議事手冊及議案參考資料」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8432-2025-12-08-1600-gaa72d","company_id":"8432","company":"東生華","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"16:00:30","subject":"本公司與兆科眼科攜手合作老花眼創新療法BCSA25","clause":"第53款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：東生華（8432），2025-12-08 16:00，「本公司與兆科眼科攜手合作老花眼創新療法BCSA25」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4172-2025-12-08-1501-1oxqq17","company_id":"4172","company":"因華","market":"興櫃","industry":"生技醫療","date":"2025-12-08","time":"15:01:56","subject":"公告本公司授權山東新時代藥業有限公司之鹽酸沙丙蝶呤片(Sapropterin Dihydrochloride)獲中國國家醫療保障局核准納入商業健康保險創新藥品目錄","clause":"第44款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：因華（4172），2025-12-08 15:01，「公告本公司授權山東新時代藥業有限公司之鹽酸沙丙蝶呤片(Sapropterin Dihydrochloride)獲中國國家」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4129-2025-12-08-1417-18mw39j","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"14:17:26","subject":"公告本公司修訂國內第五次無擔保轉換公司債發行及轉換辦法之債權人異議期間屆滿公告","clause":"第53款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2025-12-08 14:17，「公告本公司修訂國內第五次無擔保轉換公司債發行及轉換辦法之債權人異議期間屆滿公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1789-2025-12-08-1359-ag0ktz","company_id":"1789","company":"神隆","market":"上市","industry":"生技醫療","date":"2025-12-08","time":"13:59:10","subject":"本公司受邀參加永豐金證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-12-11","cite_as":"公開資訊觀測站重大訊息：神隆（1789），2025-12-08 13:59，「本公司受邀參加永豐金證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4168-2025-12-08-0810-c303az","company_id":"4168","company":"醣聯","market":"上櫃","industry":"生技醫療","date":"2025-12-08","time":"08:10:08","subject":"本公司與日本東京科學大學簽署抗體製造合約 推進HMGB1標靶抗體臨床試驗","clause":"第10款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：醣聯（4168），2025-12-08 08:10，「本公司與日本東京科學大學簽署抗體製造合約 推進HMGB1標靶抗體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}